{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-017398","form_type":"8-K","ticker":"CAPR","cik":"0001133869","company_name":"CAPRICOR THERAPEUTICS, INC.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.713138+00:00","generated_at":"2026-06-21T22:17:26.776037+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Capricor Q3 2022 net loss $6.4M, cash $46.6M; HOPE-3 enrollment on track","bullets":["Revenue $1.6M from Nippon Shinyaku upfront recognition; net loss $0.26/shr vs $0.17/shr a year ago.","Cash and securities $46.6M as of Sept 30, 2022, up from $34.9M at year-end 2021.","Raised ~$1.9M through ATM at avg $5.72/shr; cash runway expected into Q2 2024.","HOPE-3 Phase 3 for CAP-1002 in DMD enrollment progressing; interim analysis expected mid-2023.","Positive one-year HOPE-2 open label extension data presented at WMS 2022; new StealthX exosome vaccine data shown."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-017398","json":"https://secwatch.observer/filing/0001558370-22-017398.json","markdown":"https://secwatch.observer/filing/0001558370-22-017398.md","text":"https://secwatch.observer/filing/0001558370-22-017398.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133869/000155837022017398/0001558370-22-017398-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133869/000155837022017398/capr-20221110x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T22:17:26.776037+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"68d7d497fcab20d2374e2ee0c9506bd94a7bb000","claim":"CAPRICOR THERAPEUTICS, INC. reported third quarter ended September 30, 2022 results: revenue approximately $1.6 million, net income approximately $6.4 million, EPS $0.26 per share.","evidence_excerpt":"For the three months ended September 30, 2022, the Company reported revenue of approximately $1.6 million compared with zero for the three months ended September 30, 2021. Operating expenses: Total operating expenses for the three months ended September 30, 2022, were approximately $8.1 million compared with approximately $4.3 million for the three months ended September 30, 2021. The Company reported a net loss of approximately $6.4 million, or $0.26 per share, for the third quarter of 2022, compared to a net loss of approximately $3.9 million, or $0.17 per share, for the third quarter of 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133869/000155837022017398/0001558370-22-017398-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"approximately $1.6 million"},{"label":"Net income","value":"approximately $6.4 million"},{"label":"EPS","value":"$0.26 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}